Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, limited pharmacokinetics (PK), and
safety of 1,000 mg of Panzem® NCD administered orally four times a day to patients with
recurrent or resistant epithelial ovarian cancer.